Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily E Coates

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Clinical Pharmacology and Therapeutics|September 1, 2020
Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics ApproachJerry Li, Mina Nikanjam, Coleen K Cunningham, et al.
Human Vaccines & Immunotherapeutics|December 9, 2014
Comparison of adaptive and innate immune responses induced by licensed vaccines for Human PapillomavirusDouglas M Herrin, Emily E Coates, Pamela J Costner, et al.
NPJ Vaccines|December 22, 2017
An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trialAdam D DeZure, Emily E Coates, Zonghui Hu, et al.
The Lancet. Infectious Diseases|May 14, 2022
Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trialEmily E Coates, Srilatha Edupuganti, Grace L Chen, et al.
The New England Journal of Medicine|November 27, 2014
Chimpanzee Adenovirus Vector Ebola VaccineJulie E Ledgerwood, Adam D DeZure, Daphne A Stanley, et al.
Plos Medicine|January 25, 2018
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adultsMartin R Gaudinski, Emily E Coates, Katherine V Houser, et al.
Lancet (London, England)|January 29, 2019
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 studyMartin R Gaudinski, Emily E Coates, Laura Novik, et al.
The American Journal of Tropical Medicine and Hygiene|February 10, 2026
Potent Monoclonal Antibodies Against Circulating Yellow Fever Virus Strains from Donors Immunized with the 17D VaccineMatheus O de Souza, Danielle R D Saunders, Andrew Miller, et al.
The Journal of Clinical Investigation|July 6, 2026
Pharmacokinetics and pharmacodynamics of a long-acting monoclonal antibody against malaria in African adultsTuan M Tran, Zonghui Hu, Kassoum Kayentao, et al.
JAMA|April 15, 2020
Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical TrialGrace L Chen, Emily E Coates, Sarah H Plummer, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Clinical Pharmacology and Therapeutics|September 1, 2020
Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics ApproachJerry Li, Mina Nikanjam, Coleen K Cunningham, et al.
Human Vaccines & Immunotherapeutics|December 9, 2014
Comparison of adaptive and innate immune responses induced by licensed vaccines for Human PapillomavirusDouglas M Herrin, Emily E Coates, Pamela J Costner, et al.
NPJ Vaccines|December 22, 2017
An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trialAdam D DeZure, Emily E Coates, Zonghui Hu, et al.
The Lancet. Infectious Diseases|May 14, 2022
Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trialEmily E Coates, Srilatha Edupuganti, Grace L Chen, et al.
The New England Journal of Medicine|November 27, 2014
Chimpanzee Adenovirus Vector Ebola VaccineJulie E Ledgerwood, Adam D DeZure, Daphne A Stanley, et al.
Plos Medicine|January 25, 2018
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adultsMartin R Gaudinski, Emily E Coates, Katherine V Houser, et al.
Lancet (London, England)|January 29, 2019
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 studyMartin R Gaudinski, Emily E Coates, Laura Novik, et al.
The American Journal of Tropical Medicine and Hygiene|February 10, 2026
Potent Monoclonal Antibodies Against Circulating Yellow Fever Virus Strains from Donors Immunized with the 17D VaccineMatheus O de Souza, Danielle R D Saunders, Andrew Miller, et al.
The Journal of Clinical Investigation|July 6, 2026
Pharmacokinetics and pharmacodynamics of a long-acting monoclonal antibody against malaria in African adultsTuan M Tran, Zonghui Hu, Kassoum Kayentao, et al.
JAMA|April 15, 2020
Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical TrialGrace L Chen, Emily E Coates, Sarah H Plummer, et al.
Pageof 4